These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24217698)

  • 21. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
    J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
    Bertrand J; Chou M; Richardson DM; Verstuyft C; Leger PD; Mentré F; Taburet AM; Haas DW;
    Pharmacogenet Genomics; 2012 Dec; 22(12):868-76. PubMed ID: 23104099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
    Brown KC; Hosseinipour MC; Hoskins JM; Thirumaran RK; Tien HC; Weigel R; Tauzie J; Shumba I; Lamba JK; Schuetz EG; McLeod HL; Kashuba AD; Corbett AH
    Pharmacogenomics; 2012 Jan; 13(1):113-21. PubMed ID: 22111602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.
    Ciccacci C; Di Fusco D; Marazzi MC; Zimba I; Erba F; Novelli G; Palombi L; Borgiani P; Liotta G
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1909-16. PubMed ID: 23774940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.
    Enimil A; Antwi S; Yang H; Dompreh A; Alghamdi WA; Gillani FS; Orstin A; Bosomtwe D; Opoku T; Norman J; Wiesner L; Langaee T; Peloquin CA; Court MH; Greenblatt DJ; Kwara A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.
    Fan-Havard P; Liu Z; Chou M; Ling Y; Barrail-Tran A; Haas DW; Taburet AM;
    Antimicrob Agents Chemother; 2013 May; 57(5):2154-60. PubMed ID: 23459477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.
    Oluka MN; Okalebo FA; Guantai AN; McClelland RS; Graham SM
    AIDS Res Ther; 2015; 12():10. PubMed ID: 25878720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.
    Bienczak A; Cook A; Wiesner L; Mulenga V; Kityo C; Kekitiinwa A; Walker AS; Owen A; Gibb DM; Burger D; McIlleron H; Denti P
    J Antimicrob Chemother; 2017 Jan; 72(1):190-199. PubMed ID: 27707991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
    Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
    Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
    Mahungu T; Smith C; Turner F; Egan D; Youle M; Johnson M; Khoo S; Back Dj; Owen A
    HIV Med; 2009 May; 10(5):310-7. PubMed ID: 19228205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
    Jamshidi Y; Moreton M; McKeown DA; Andrews S; Nithiyananthan T; Tinworth L; Holt DW; Sadiq ST
    J Antimicrob Chemother; 2010 Dec; 65(12):2614-9. PubMed ID: 20952418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.
    Lehr T; Yuan J; Hall D; Zimdahl-Gelling H; Schaefer HG; Staab A; MacGregor TR; Jayadev S
    Pharmacogenet Genomics; 2011 Nov; 21(11):721-30. PubMed ID: 21860339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C; Cressey TR; Prapaithong P; Tawon Y; Pasomsub E; Srichunrusami C; Jantararoungtong T; Lallement M; Chantratita W
    Br J Clin Pharmacol; 2012 Dec; 74(6):1005-12. PubMed ID: 22471906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
    Arab-Alameddine M; Di Iulio J; Buclin T; Rotger M; Lubomirov R; Cavassini M; Fayet A; Décosterd LA; Eap CB; Biollaz J; Telenti A; Csajka C;
    Clin Pharmacol Ther; 2009 May; 85(5):485-94. PubMed ID: 19225447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
    Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
    J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Chokephaibulkit K; Cressey TR; Capparelli E; Sirisanthana V; Muresan P; Hongsiriwon S; Ngampiyaskul C; Limwongse C; Wittawatmongkol O; Aurpibul L; Kabat B; Toye M; Smith ME; Eksaengsri A; McIntosh K; Yogev R;
    Antivir Ther; 2011; 16(8):1287-95. PubMed ID: 22155910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.
    Gozalo C; Gérard L; Loiseau P; Morand-Joubert L; Peytavin G; Molina JM; Dellamonica P; Becquemont L; Aboulker JP; Launay O; Verstuyft C;
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):513-20. PubMed ID: 21824325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
    Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.